FRANKLIN LAKES, New Jersey
,
October 3, 2022
(press release)
–
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that Eric Borin has been named president of Medication Delivery Solutions (MDS) for BD, effective today. Borin, 55, will be responsible for driving global strategic, operational and commercial performance of the MDS business unit and will report to Mike Garrison, executive vice president (EVP) and president of the Medical segment. Borin succeeds Rick Byrd who was recently promoted to EVP and president of the Interventional segment at BD. Since 2020, Borin has been president of the Pharmaceutical Systems business for BD. "Eric has more than 25 years of BD leadership experience and is well suited to lead MDS - BD's largest business unit by revenue," said Garrison. "Over the past two years, Eric has led Pharmaceutical Systems to become one of the highest growth business units for BD and increased revenue well above BD's long-term target. He has also positioned the business for the future by enabling the development of several innovative new drug delivery platforms to develop transformative solutions for the pharmaceutical industry and patients around the world." Borin joined BD in 1996 as a technical service manager in Pharmaceutical Systems and has held numerous leadership positions in the business. In 2010, Borin was named vice president (VP) and general manager (GM) of the North America region for Diabetes Care and then moved to the same role for Pharmaceutical Systems. In 2014, Borin was promoted to VP and GM of BD Rx, a business he led until BD divested it to Fresenius Kabi USA. In 2016, he rejoined Diabetes Care as VP and GM of the U.S. region and was then named VP and GM of Infusion Specialty Disposables in 2017, which is part of the MDS business unit. In 2020, Borin was promoted to president of Pharmaceutical Systems. Borin earned his Bachelor of Science in Mechanical Engineering from Manhattan College. About BD BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 75,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/ and Twitter @BDandCo. Contacts: Media: Investors: Troy Kirkpatrick Francesca DeMartino VP, Public Relations SVP, Head of Investor Relations 858.617.2361 201.847.5743 troy.kirkpatrick@bd.com francesca.demartino@bd.com Attachments Original Link BD - Becton, Dickinson and Company published this content on 03 October 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 03 October 2022 14:34:55 UTC. (C) Copyright 2022 - BD - Becton, Dickinson and Company
Original Document
Permalink
Disclaimer
* All content is copyrighted by Industry Intelligence, or the original respective author or source. You may not recirculate, redistrubte or publish the analysis and presentation included in the service without Industry Intelligence's prior written consent. Please review our terms of use.
